Anavex Life Sciences Corp. [NASDAQ: AVXL] slipped around -0.96 points on Friday, while shares priced at $11.87 at the close of the session, down -7.48%. The company report on March 4, 2021 that Anavex Life Sciences to Present at the H.C. Wainwright Global Life Sciences Conference.
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at the H.C. Wainwright Global Life Sciences Conference being held from March 9-10, 2021.
A webcast of the on-demand presentation will be available beginning Tuesday, March 9, 2021 on the Company’s website at www.anavex.com.
Anavex Life Sciences Corp. stock is now 119.81% up from its year-to-date (YTD) trading value. AVXL Stock saw the intraday high of $12.99 and lowest of $10.95 per share. The company’s 52-week high price is 28.70, which means current price is +131.84% above from all time high which was touched on 02/04/21.
Compared to the average trading volume of 4.12M shares, AVXL reached a trading volume of 2648590 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Anavex Life Sciences Corp. [AVXL]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AVXL shares is $15.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AVXL stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Anavex Life Sciences Corp. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 16, 2020. While these analysts kept the previous recommendation, Ladenburg Thalmann raised their target price to Buy. The new note on the price target was released on September 28, 2020, representing the official price target for Anavex Life Sciences Corp. stock.
The Average True Range (ATR) for Anavex Life Sciences Corp. is set at 1.92 The Price to Book ratio for the last quarter was 16.49.
How has AVXL stock performed recently?
Anavex Life Sciences Corp. [AVXL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -8.83. With this latest performance, AVXL shares gained by 14.35% in over the last four-week period, additionally plugging by 183.29% over the last 6 months – not to mention a rise of 182.62% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AVXL stock in for the last two-week period is set at 51.81, with the RSI for the last a single of trading hit 44.76, and the three-weeks RSI is set at 55.30 for Anavex Life Sciences Corp. [AVXL]. The present Moving Average for the last 50 days of trading for this stock 9.00, while it was recorded at 13.00 for the last single week of trading, and 5.75 for the last 200 days.
Anavex Life Sciences Corp. [AVXL]: Deeper insight into the fundamentals
Return on Total Capital for AVXL is now -130.83, given the latest momentum, and Return on Invested Capital for the company is -110.59. Return on Equity for this stock declined to -110.59, with Return on Assets sitting at -87.79.
Reflecting on the efficiency of the workforce at the company, Anavex Life Sciences Corp. [AVXL] managed to generate an average of -$1,314,023 per employee.Anavex Life Sciences Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.80 and a Current Ratio set at 6.80.
Earnings analysis for Anavex Life Sciences Corp. [AVXL]
With the latest financial reports released by the company, Anavex Life Sciences Corp. posted -0.12/share EPS, while the average EPS was predicted by analysts to be reported at -0.15/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 20.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AVXL.
Insider trade positions for Anavex Life Sciences Corp. [AVXL]
There are presently around $167 million, or 20.40% of AVXL stock, in the hands of institutional investors. The top three institutional holders of AVXL stocks are: BLACKROCK INC. with ownership of 3,678,763, which is approximately 4.545% of the company’s market cap and around 3.63% of the total institutional ownership; VANGUARD GROUP INC, holding 2,896,891 shares of the stock with an approximate value of $34.39 million in AVXL stocks shares; and STATE STREET CORP, currently with $10.38 million in AVXL stock with ownership of nearly -1.788% of the company’s market capitalization.
Positions in Anavex Life Sciences Corp. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 48 institutional holders increased their position in Anavex Life Sciences Corp. [NASDAQ:AVXL] by around 2,019,258 shares. Additionally, 29 investors decreased positions by around 710,275 shares, while 20 investors held positions by with 11,373,544 shares. The mentioned changes placed institutional holdings at 14,103,077 shares, according to the latest SEC report filing. AVXL stock had 20 new institutional investments in for a total of 1,302,483 shares, while 5 institutional investors sold positions of 82,823 shares during the same period.